CZCarlos Zúñiga-Ramírez

Carlos Zúñiga-Ramírez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlos Zúñiga-Ramírez has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cerebrotendinous Xanthomatosis

    by Héctor Rubén Martínez-Hernández, Leonel Villa-Villegas, Carlos Eduardo Piña-Avilés, Roberto Leal-Ortega, Michel Sáenz-Farret, Alejandra Camacho-Molina, Carlos Zúñiga-Ramírez

  • LLM-Guided Refinement of Clinical Instruments: A Reproducible Framework with Expert Validation

    by Marco Antonio Gutiérrez Sevilla, Emma Guadalupe Fajardo Zubieta, Roberto Cong Torres, Fernando Aaron Osuna Gallego, Mariana Aurora Cansino Torres, Carlos Zuñiga Ramirez, German Preciat

  • Open Access

    Association Between Ultrasound Diaphragmatic Measurements and Mechanical Ventilation in Patients With Guillain-Barré Syndrome

    by Carlos Javier Moreno-Bernardino, Beatriz Alejandra Ramirez-Mora, Paola Alejandra Álvarez-López, Bryan Escamilla-Velazquez, Kevin Sylvain Herrmann Villatoro, Francisco Javier González López, Carlos Hurtado Delgado, Omar Cardenas-Saenz, Amado Jimenez-Ruiz, Lilia Georgina Aguilar-Parra, et al.

    Background and ObjectivesRespiratory failure is a serious complication in Guillain-Barré syndrome (GBS). Traditional clinical scales have limitations in accurately predicting the need for invasive ...

  • Open Access

    Epidemiology and clinical features of movement disorders in a Mexican Mestizo cohort: a 10-year tertiary-center study

    by Katia Carmina Farias-Moreno, Leonel Villa-Villegas, Biagio David González-Ruffino, Luz Gabriela Lira-Jaime, Karla Berenice Carrazco-Peña, Enrique Gómez-Figueroa, Carlos Zúñiga-Ramírez

    Movement disorders comprise a heterogeneous spectrum of neurological conditions characterized by impaired motor control. Limited epidemiological data exist for Latin American populations, particularly for Mexican Mestizos. To characterize the epidemiological profile and clinical features of movement disorders in a large cohort of Mexican Mestizo patients evaluated at a public tertiary referral center in western Mexico. We conducted a 10-year retrospective cohort study (2012–2022) analyzing medical records from the Movement Disorders and Neurodegenerative Diseases Unit at the Hospital Civil de Guadalajara, a public tertiary university hospital from the western region of Mexico. Inclusion criteria were confirmed movement disorder diagnosis and a minimum of two clinical evaluations. Binary logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs). Among 1,830 records (mean age 58.5 ± 17.0 years, 53.9% female, all self-identified as Mexican Mestizo), hypokinetic disorders comprised 63.9% (n = 1,170) and hyperkinetic disorders 36.1% (n = 660). Parkinsonism (63.6%, n = 1,163) and tremor (11.3%, n = 206) were the most frequent subtypes. Hypokinetic disorders were associated with older age (64.2 ± 12.8 vs. 48.5 ± 18.9 years, p < 0.001), hypertension (OR = 2.29; 1.78–2.95; p = 0.001), and smoking (OR = 1.51; 1.13–2.03; p = 0.005). Hyperkinetic disorders were associated with male sex (OR = 1.47; 1.19–1.82; p < 0.001), family history (OR = 1.92; 1.49–2.47; p < 0.001), and functional presentations (OR = 11.0; 5.53–22.14; p < 0.001). This is the largest reported Mexican Mestizo cohort with movement disorders evaluated in a single public tertiary center. Findings reveal distinct demographic and clinical patterns and may inform integrated cardiovascular–neurological care models, screening protocols, and resource allocation within the Mexican public health system.


  • Open Access

    “Deep Brain Stimulation of the Ventral Intermediate Nucleus of the Thalamus for Tremor in Polr3a-Related Tremor-ataxia Syndrome: A Two-case Report”

    by Edgar Javier Sánchez-Román, Leonel Villa-Villegas, Roberto Leal-Ortega, Luz Gabriela Lira-Jaime, Francisco Rivas-Ruvalcaba, Karely Díaz-Ramírez, Carlos Eduardo Piña-Avilés, Rodrigo Mercado-Pimentel, Carlos Zúñiga-Ramírez

    Clinical Vignette: RNA polymerase III subunit A (POLR3A) related disorders are a group of heterogeneous diseases with a recessive autosomic inheritance. These disorders manifest with distinct clinical features like ataxia, spasticity, hypodontia, hypogonadism, mental retardation and progressive motor decline. Clinical Dilemma: POLR3A gene mutation can manifest with parkinsonism, dystonia, ataxia and tremor. Deep brain stimulation (DBS) might be effective for motor symptoms. Choosing the best DBS target is essential for successful treatment. Case reports and Clinical Solution: Two subjects with a predominant tremorous syndrome due to POLR3A gene mutation with no response to pharmacological treatment underwent DBS at ventral intermediate nuclei (Vim DBS) of thalamus, with significant improvement in tremor. Gap in Knowledge: Tremor in POLR3A gene mutation could respond to Vim DBS.

  • Open Access

    Deep Brain Stimulation in Leigh-Like Syndrome Due to DNM1 Pathogenic Variant

    by Leonel Villa-Villegas, Luz Gabriela Lira-Jaime, Katia Carmina Farías-Moreno, Biagio David González-Ruffino, Alberto Soto-Escageda, Rodrigo Mercado-Pimentel, Carlos Eduardo Piña-Avilés, Carlos Zúñiga-Ramírez

    Clinical vignette: Leigh syndrome (LS) and Leigh-like syndromes (LLS), now collectively referred to as Leigh Syndrome Spectrum (LSS), encompass a wide range of clinical manifestations, including epilepsy, neurodevelopmental delay, and movement disorders such as ataxia, chorea, and dystonia. Although rare, LSS can present atypical symptoms in certain cases. The primary etiological cause of LSS is genetic, resulting from mitochondrial alterations. Clinical dilemma: Hyperkinesias in LSS or other mitochondrial disorders can be disabling, leading to a significant reduction in the patient’s quality of life. Clinical solution: Globus pallidum deep brain stimulation (GPi-DBS) surgery is an effective treatment for hyperkinesias, such as chorea, and dystonia, caused by mitochondrial defects. Gap in knowledge: Pathogenic DNM1-related mitochondrial disorders with Leigh syndrome phenotype may show long-term improvement of hyperkinetic movements after GPi-DBS.


  • Open Access

    The costs and benefits of deep brain stimulation in Parkinson's disease: a review and social network analysis

    by Carlos Zúñiga-Ramírez, Katia Carmina Farías-Moreno, Gabriel Moreno, Enrique Gómez-Figueroa, Hernando Efraín Caicedo-Ortíz, José Damián Carrillo-Ruíz

    Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Levodopa has been considered the best treatment option. However, deep brain stimulation (DBS) use has increased over time, mostly when levodopa-related complications arise.To review the current evidence regarding economic evaluations assessing costs and benefits comparing pharmacological versus surgical treatment among subjects with PD.We searched three databases (PubMed, Embase, and Google Scholar) for studies comparing levodopa treatment and DBS among subjects with PD in terms of costs and benefits from therapy.Out of the 107 studies identified, 14 met the inclusion criteria. Most of the published studies were from Europe. Incremental cost-effectiveness ratios have shown variable results, from -€979 to €6,729 per change of 1 point in the score on part III of the Unified Parkinson's Disease Rating Scale (UPDRS III), while incremental cost-utility ratios depict values as low as €6,700 and as high as $704,906.03 per quality-adjusted life-years (QALY).We observed a higher cost during the 1st year of DBS implantation due to the surgical procedure itself, subsequently, there was a trend for a lower cost over the following years, with no loss of benefit. Overall, the studies showed DBS as a cost-effective measure at 5-years after implantation.


  • Contribution of Stroke to Long-Term All-Cause and Cause-Specific Mortality in Mexico City

    by Enrique Gomez-Figueroa, José Luis Ruiz-Sandoval, Andrea Margarita De Alba-Sánchez, Omar Cárdenas-Sáenz, Carlos Zúñiga-Ramírez, Raúl Amavisca-Espinosa, Fátima Macías-Ortiz, Amado Jímenez-Ruiz

    Stroke mortality is more common in low-income and middle-income nations such as Mexico. Prognosis data typically rely on short-term hospital follow-ups, revealing high mortality rates due to systemic complications and early recurrence. We aim to explore stroke's long-term impact by examining all-cause and cause-specific mortality. We analyzed data from the Mexico City Prospective Study (1998-2004) with known mortality outcomes until December 2022. Baseline variables were compared between participants who had stroke and nonstroke participants. Cox proportional hazard regression assessed each variable's contribution to overall mortality. Subsequent analysis within the stroke subgroup aimed to identify unique risk factors of mortality, using Cox regression models adjusted for age, sex, and time since stroke. Among 145,537 eligible participants, 1,492 (1.0%) had a history of stroke. Participants who had stroke were older (57.58 vs 50.16, p < 0.001); had lower mean weekly income ($108.24 vs $176.14, p < 0.001); had higher alcohol intake and smoking frequency; and had more frequent comorbidities such as hypertension (48.9 vs 19.3%, p < 0.001), diabetes (23.4 vs 12.9%, p < 0.001), and ischemic heart disease (5.4 vs 1.0%, p < 0.001). They had a significantly increased risk of death from any cause (hazard ratio [HR] 2.59, 95% CI 2.37-2.83, p < 0.001). Deceased participants with stroke were more likely to be male, with a higher prevalence of diabetes, hypertension, and abnormal waist-hip index. Stroke increased the risk of death from cardiac (HR 3.56, 95% CI 3.02-4.19, p < 0.001), renal (HR 2.05, 95% CI 1.58-2.66, p < 0.001), and pulmonary (HR 2.29, 95% CI 1.79-2.92, p < 0.001) causes. This study confirms stroke's association with higher mortality rates, especially from cardiac, renal, and pulmonary causes in Mexico. It underscores the elevated prevalence of cardiovascular comorbidities and adverse socioeconomic profiles among participants who had stroke and those who died with a history of stroke.


  • Open Access

    Clinical predictors for mechanical ventilation assistance in Guillain-Barré syndrome

    by Axel Abel Rodríguez-Méndez, Jaime Briseño-Ramírez, Francisco Javier Rivas-Ruvalcaba, Javier Solis-Estrada, Liliana Berenice Alcázar-García, Karely Díaz-Ramírez, Gabriela Lira-Jaime, Edgar Javier Sánchez-Román, Carlos Zúñiga-Ramírez

    Background: Guillain-Barré syndrome (GBS) frequently leads to respiratory failure and autonomic dysfunction, resulting in approximately one-third of patients requiring mechanical ventilation.Objective: This study aimed to identify clinical predictors for mechanical ventilation in patients with GBS.Methods: This research was conducted from 2010 to 2021 using registries from a tertiary hospital in an upper middle-income Latin American country. Participants were categorized into two groups based on their ventilation status. Demographic data were collected, and independent predictors of the need for mechanical ventilation were determined through multivariate logistic regression analysis.Results: Dysautonomic events occurred in 36% of the patients, with 17% requiring mechanical ventilation; the average duration of intubation was 1.16 ± 3.18 days. The multivariate analysis indicated that bulbar dysfunction significantly increased the likelihood of requiring mechanical ventilation by 19-fold (OR 18.67, 95% CI 5.85–59.42), followed by ophthalmoplegia, which increased the likelihood by sixfold (OR 5.68, 95% CI 1.28–25.19).Conclusion: Bulbar dysfunction, dysautonomia, and lower Medical Research Council (MRC) scores were significant predictors of the need for mechanical ventilation in hospitalized GBS patients. These findings support the need for close monitoring and early admission to the intensive care unit (ICU) admission for at-risk patients.


  • Ataxia due to a COQ8A Novel Variant in Primary Coenzyme Q10 Deficiency

    by Gerardo Chavira‐Hernández, Carlos Eduardo Piña‐Avilés, Carlos Zúñiga‐Ramírez